Mechanisms of Disease: angiogenesis and the management of breast cancer

被引：113

作者：

Banerjee, Susana ^{[1
]}

Dowsett, Mitch ^{[1
]}

Ashworth, Alan ^{[1
]}

Martin, Lesley-Ann ^{[1
]}

机构：

[1] Royal Marsden Hosp, Inst Canc Res, Acad Dept Biochem, London SW3 6JJ, England

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 09期

关键词：

bevacizumab; breast cancer; hypoxia; receptor tyrosine kinase; inhibitor; VeGF;

D O I：

10.1038/ncponc0905

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Demonstration of the clinically significant activity of bevacizumab in breast cancer has attracted a great deal of interest. Numerous other antiangiogenic treatments are in clinical development and some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. In this Review, we discuss the potential of various components of the angiogenic pathway as prognostic and predictive factors in breast cancer. In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer.

引用

页码：536 / 550

页数：15

共 117 条

[51] Tumor biology - Herceptin acts as an anti-angiogenic cocktail [J].

Izumi, Y ;

Xu, L ;

di Tomaso, E ;

Fukumura, D ;

Jain, RK .

NATURE, 2002, 416 (6878) :279-280

[52] Lessons from phase III clinical trials on anti-VEGF therapy for cancer [J].

Jain, RK ;

Duda, DG ;

Clark, JW ;

Loeffler, JS .

NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01) :24-40

[53] Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].

Jain, RK .

SCIENCE, 2005, 307 (5706) :58-62

[54] Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis [J].

Jin, QR ;

Hemminki, K ;

Enquist, K ;

Lenner, P ;

Grzybowska, E ;

Klaes, R ;

Henriksson, R ;

Chen, BW ;

Pamula, J ;

Pekala, W ;

Zientek, H ;

Rogozinska-Szczepka, J ;

Utracka-Hutka, B ;

Hallmans, G ;

Försti, A .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3647-3653

[55] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J].

Johnson, DH ;

Fehrenbacher, L ;

Novotny, WF ;

Herbst, RS ;

Nemunaitis, JJ ;

Jablons, DM ;

Langer, CJ ;

DeVore, RF ;

Gaudreault, J ;

Damico, LA ;

Holmgren, E ;

Kabbinavar, F .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2184-2191

[56] Predicting benefit from anti-angiogenic agents in malignancy [J].

Jubb, Adrian M. ;

Oates, Adam J. ;

Holden, Scott ;

Koeppen, Hartmut .

NATURE REVIEWS CANCER, 2006, 6 (08) :626-635

[57] INHIBITION OF VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR ACTIVITY BY AN ENDOGENOUSLY ENCODED SOLUBLE RECEPTOR [J].

KENDALL, RL ;

THOMAS, KA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10705-10709

[58] Clinical translation of angiogenesis inhibitors [J].

Kerbel, R ;

Folkman, J .

NATURE REVIEWS CANCER, 2002, 2 (10) :727-739

[59]

Kerbel RS, 2001, J CLIN ONCOL, V19, p45S

[60] Hypoxia-inducible factor-1 in human breast and prostate cancer [J].

Kimbro, K. S. ;

Simons, J. W. .

← 1 2 3 4 5 6 7 8 9 10 →